Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes

Next Previous
Trial Profile

A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABI 1179 (Primary)
  • Indications Herpes simplex virus infections
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
  • Sponsors Assembly Biosciences

Most Recent Events

  • 06 Aug 2025 According to an Assembly Biosciences media release, company is on track for proof-of-concept Phase 1b data no later than this fall in participants with long-acting herpes simplex virus (HSV).
  • 26 Jul 2025 According to an Assembly Biosciences media release, data from this trial are featured in multiple poster presentations, including one late-breaker, during the STI & HIV 2025 World Congress, taking place July 26-30, 2025, in Montreal, Canada, as well as in oral and poster presentations at the 49th Annual International Herpesvirus Workshop, taking place July 26-30, 2025, in Berlin, Germany.
  • 30 Jun 2025 According to an Assembly Biosciences media release, the trial results will support dose selection for future clinical trials and the company expects to submit data from this trial for presentation at future scientific meetings.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top